S100B Is Not a Reliable Prognostic Index in Paediatric TBIPiazza O.a · Storti M.P.a · Cotena S.b · Stoppa F.b · Perrotta D.b · Esposito G.c · Pirozzi N.b · Tufano R.a
aDepartment of Anaesthesia and Intensive Care, University of Naples ‘Federico II’, and bEmergency Department, ‘Bambino Gesù’ Children’s Hospital, Rome, and cDepartment of Clinical Pathology, IRCCS ‘G. Pascale’, Naples, Italy
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: As far as paediatric traumatic brain injury is concerned, it is difficult to quantify the extent of the primary insult, to monitor secondary changes and to predict neurological outcomes by means of the currently used diagnostic tools: physical examination, Glasgow Coma Scale (GCS) score and computed tomography. For this reason, several papers focused on the use of biochemical markers (S100B, neuron-specific enolase) to detect and define the severity of brain damage and predict outcome after traumatic head injury or cardiac arrest. Objective: The aim of this paper is measuring the range of S100B serum concentrations in children affected by traumatic brain injury and describing the possible roles of this protein in the reaction to trauma. Methods: Fifteen children aged 1–15 years were included in the study. Traumatic brain injury severity was defined by paediatric GCS score as mild (9 patients), moderate (2 patients) or severe (4 patients). Blood samples for S100B serum measurement were taken at emergency department admission and after 48 h. Results: The serum S100B concentration was higher in the group of severe trauma patients, who scored the lowest on the GCS at admission, and among them, the highest values were reported by the children with concomitant peripheral lesions. Conclusions: The role of S100B in paediatric traumatic brain injury has not been clarified yet, and the interpretation of its increase when the head trauma is associated with other injuries needs the understanding of the physiopathological mechanisms that rule its release in the systemic circulation. The levels of S100B in serum after a brain injury could be related to the mechanical discharge from a destroyed blood-brain barrier, or they could be due to the active expression by the brain, as a part of its involvement in the systemic inflammatory reaction. Early increase of this protein is not a reliable prognostic index of neurological outcome after pediatric traumatic brain injury, since even very elevated values are compatible with a complete neurological recovery.
© 2007 S. Karger AG, Basel
- Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G: Serum S100 B levels for trauma patients without head injuries. Neurosurgery 2001;48:1255–1258.
- Donato R: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33:637–638.
- Maschmann J, Erb MA, Heinemann MK, et al: Evaluation of protein S-100 serum concentrations in healthy newborns and seven newborns with perinatal acidosis. Acta Paediatr 2000;89:533–535.
- Nagdyman N, Komen W, Ko H, et al: Early biochemical indicators of hypoxic-ischemic encephalopathy after birth asphyxia. Pediatr Res 2001;49:502–506.
- Spinella PC, Dominguez T, Drott HR, Huh J, McCormick L, Rajendra A, Argon J, McIntosh T, Helfaer M: S-100 beta protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury. Crit Care Med 2003;31:939–945.
- Marshall L, Becker D, Bowers S, et al: The National Traumatic Coma Data Bank. 1. Design, purpose, goals and results. J Neurosurg 1983;59:276–284.
- Pietrini D, Savioli A, Grossetti R, et al: SIAARTI-SARNePI linee guida per il trattamento del trauma cranico pediatrico grave. Minerva Anestesiol 2004;70:549.
- Cecchetti C, Stoppa F, Vanacore N, Barbieri MA, Raucci U, Pasotti E, Tomasello C, Marano M, Pirozzi N: Monitoraggio della volemia intratoracica e della performance cardiaca in pazienti pediatrici in terapia intensiva. Minerva Anestesiol 2003;69:907.
- Piazza O, Cotena S, Esposito G, De Robertis E, Tufano R: S100B is a sensitive but non specific prognostic index in comatose patients after cardiac arrest. Minerva Chir 2005;60:477–480.
Koide M, Kunii Y, Moriki N, Ayusawa Y, Sakai A: Clinical significance of serum S-100 beta protein level after pediatric cardiac surgery. Jpn J Thorac Cardiovasc Surg 2002;50:280–283.
- Ispida K, Gohara T, Kawata R, Ohtake K, Morimoto Y, Sakabe T: Are serum S100beta proteins and neuron-specific enolase predictors of cerebral damage in cardiovascular surgery? J Cardiothorac Vasc Anesth 2003;17:4–9.
- Snyder-Ramos SA, Gruhlke T, Bauer H, Bauer M, Luntz AP, Motsch J, Martin E, Vahl CF, Missler U, Wiesmann M, Bottiger BW: Cerebral and extracerebral release of protein S100B in cardiac surgical patients. Anaesthesia 2004;59:344–349.
- McKeating EG, Andrews PJD, Mascia L: Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir Suppl 1998;71:117–119.
- Sahlein DH, Heyer EJ, Rampersad A, Winfree CJ, Solomon RA, Benvenisty AI, Quest DO, Du E, Connolly ES: Failure of intraoperative jugular bulb S-100B and neuron-specific enolase sampling to predict cognitive injury after carotid endarterectomy. Neurosurgery 2003;53:1243–1250.
Piazza O, Palomba R, Esposito G: S100B serum levels increase in postoperative patients. Acute Pain DOI:10.1016/j.acpain.2006.03. 002.
- Liu L, Li Y, Van Eldik LJ, Griffin WST, Barger SW: S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem 2005;92:546–553.
- Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ, Griffin WST: In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 1996;17:761–766.
- Mrak RE, Griffin WST: The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer’s disease. Neurobiol Aging 2001;22:915–922.
- Li Y, Barger SW, Mrak RE, Griffin WST: S100β induction of the proinflammatory cytokine interleukin-6 in neurons. J Neurochem 2000;74:143–150.
- Ozatik MA, Tarcan O, Kale A, Askin GA, Balci M, Undar A, Kucukaksu DS, Sener E, Tasdemir O: Do S100beta protein level increases due to inflammation during cardiopulmonary bypass occur without any neurological deficit? Perfusion 2002;17:335–338.
Yang Y, Huang W, Xueying L: Early changes of endotheline, nitric oxide and arginine vasopressin in patients with acute cerebral injury. Chin J Traumatol (Eng ed) 2002;5:529–562.
- Bemana I, Takahashi E, Nakamura T, Kuyama H, Nagao S: OPC-21268, an orally effective, nonpeptide arginine vasopressin V1 receptor antagonist reduces vasogenic brain edema. Acta Neurochir Suppl 1997;70:194–197.
- Kagawa M, Nagao S, Bemana I: Arginine vasopressin receptor antagonists for treatment of vasogenic brain edema: an experimental study. J Neurotrauma 1996;13:273–279.
- Szmydynger-Chodobska J, Chung I, Kozniewske E, Tran B, Harrington FJ, Duncan JA, Chadobsky A: Increased expression of vasopressin V1a receptors after traumatic brain injury. J Neurotrauma 2004;21:1090–1102.
- Ikeda Y, Teramoto A, Nakagawa Y, Ishibashi Y, Yoshii T: Attenuation of cryogenic induced brain oedema by arginine vasopressin release inhibitor RU51599. Acta Neurochir (Wien) 1997;139:1173–1179.
Huang W, Yang Y, Wu S, Jin Z, Bao D, Gan H: Early changes of arginine vasopressin and angiotensin II in patients with acute cerebral injury. Chin J Traumatol (Eng ed) 2001;4:161–163.
Kochanek PM, Berger RP, Jenkins LW: Biochemical and molecular mechanisms after severe traumatic brain injury; in Vincent JL (ed): Yearbook of Intensive Care and Emergency Medicine. Berlin, Springer, 2002, pp 688–698.
- Whitelaw A, Rosengren L, Blennow M: Brain specific proteins in posthaemorragic ventricular dilatation. Arch Dis Child Fetal Neonatal 2001;84:F90–F91.
- Mussack T, Biberthaler P, Kanz KG, et al: Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. Crit Care Med 2002;30:2669–2674.
- Missler U, Wiesmann M, Wittmann G: Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem 1999;45:138–141.
- Petzold A, Green AJE, Keir G: Role of S-100B as an early predictor of high intracranial pressure and mortality in brain injury: a pilot study. Crit Care Med 2002;30:2705–2710.
- Woertgen C, Rothoerl RD, Metz C, et al: Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma 1999;47:1126–1130.
- Biberthaler P, Mussack T, Wiedeman E, et al: Evaluation of S-100b as a specific marker for neuronal damage due to minor head trauma. World J Surg 2001;25:93–97.
- Pelinka LE, Toegel E, Mauritz W, Redl H: Serum S-100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. Shock 2003;19:195–200.
- Abdul-Khaliq H, Schubert S, Stoltenburg-Didinger G, Huebler M, Troitzsch D, Wehsack A, Boettcher W, Schwaller B, Crausaz M, Celio M, Schroter ML, Blasig IE, Hetzer R, Lange PE: Release patterns of astrocytic and neuronal biochemical markers in serum during and after experimental settings of cardiac surgery. Restor Neurol Neurosci 2003;21:141–150.
- Guan W, Yang YL, Xia WM, Li L, Gong DS: Significance of serum neuron-specific enolase in patients with acute traumatic brain injury. Chin J Traumatol 2003;6:218–221.
Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM: Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 2005;103(suppl 1):61–68.
- Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RSB, Ruppel RA, Kochanek PM: Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 2002;109:E31.
- Fridriksson T, Kini N, Walsh-Kelly C, Hennes H: Serum neuron-specific enolase as a predictor of intracranial lesions in children with head trauma: a pilot study. Acad Emerg Med 2000;7:816–820.
- Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T: Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol 1995;43:267–270.
- Pelinka LE, Hertz H, Mauritz W, Harada N, Jafarmadar M, Albrecht M, Redl H, Bahrami S: Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock 2005;24:119–123.
- Pelinka LE, Jafarmadar M, Redl H, Bahrami S: Neuron-specific enolase is increased in plasma after hemorrhagic shock and after bilateral femur fracture without traumatic brain injury in the rat. Shock 2004;22:88–91.
- Verdu Perez A, Falero MP, Arroyos A, Estevez F, Felix V, Lopez Y, Pantoja A, Ureta A: Blood neuronal specific enolase in newborns with perinatal asphyxia. Rev Neurol 2001;32:714–717.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.